December 6, 2024 01:32 PM EST
Deals
FDA+
Manufacturing

Eu­ro­pean Com­mis­sion green­lights $16.5B No­vo-Catal­ent ac­qui­si­tion 

Anna Brown

News Reporter

De­spite months of bio­phar­ma in­dus­try push­back, the Eu­ro­pean Com­mis­sion has un­con­di­tion­al­ly ap­proved No­vo Hold­ings’ $16.5 bil­lion ac­qui­si­tion of Catal­ent.

The Fed­er­al Trade …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Gala­pa­gos to split in­to two com­pa­nies, slash head­count as it eyes turn­around

Maze files for first biotech IPO of 2025, fol­low­ing $115M fund­ing boost

Vir’s ear­ly T cell en­gager da­ta of­fer first look at can­cer piv­ot, stock jumps

Every FDA drug ap­proval from 2024: Few­er nods, but long-await­ed treat­ments cross the fin­ish line

No­vo ex­pands pact with Flag­ship's Va­lo to in­clude obe­si­ty, di­a­betes for $190M near-term

ARCH, F-Prime and Mubadala pump $200M in­to for­mer De­nali pro­grams

A service from the Financial Times